Michael Miller, MD
Cardiovascular Disease · Philadelphia, PANPI 1235178559
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $97,288 of the $132,876 with a category attached, or 73.2%. Amarin Pharma, Inc. accounts for 89.8% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $42,590 and has fallen 65.2% since, to $14,813 in 2025. Among cardiovascular disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 85 payments — averaging $1563.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$119K
- Pfizer$9K
- Novo Nordisk$3K
- Seqirus USA Inc$2K
- Abbott$98
- Stryker$56
- plus $90 from 3 others
Across 67 payments — averaging $1439.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kowa Research Institute, Inc.$57K
- Novo Nordisk AS$39K
- Novartis$781
What the payments were for
- Consulting fees$97,28873%
- Speaking & faculty fees$21,48016%
- Travel & lodging$12,2169%
- Food & beverage$1,8931%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 73 | $119,324 |
| Pfizer | 4 | $8,760 |
| Novo Nordisk | 1 | $2,748 |
| Seqirus USA Inc | 1 | $1,800 |
| Abbott | 1 | $98 |
| Stryker | 1 | $56 |
| Ionis Pharmaceuticals, Inc. | 1 | $47 |
| Misonix Inc | 2 | $23 |
| Atricure, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$117,804
How this compares
$132,876 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ezetimibe | 15 | $747 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Philadelphia
- Paul ForfiaPhiladelphia$1.2M
- Quang BuiPhiladelphia$933K
- Dean KaralisPhiladelphia$385K
- Manavendra BakhshiPhiladelphia$250K
- Philip HainesPhiladelphia$170K
- Julio ChirinosPhiladelphia$145K
- Nehal MehtaPhiladelphia$129K
- Garo GaribianPhiladelphia$115K
- Norman FeinsmithPhiladelphia$94K
- Brian DrachmanPhiladelphia$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.